World’s Fastest PCR-Based SARS-CoV-2 Test Now Available on Randox-Bosch’s POC Vivalytic Analyzer – COVID-19



[ad_1]

Image: World's fastest PCR-based SARS-CoV-2 test now available on the POC Randox-Bosch Vivalytic analyzer (Photo courtesy of Bosch Healthcare)

Image: World’s fastest PCR-based SARS-CoV-2 test now available on the POC Randox-Bosch Vivalytic analyzer (Photo courtesy of Bosch Healthcare)

A new rapid coronavirus test, providing results for COVID-19 in just 39 minutes, is now available from Vivalytic, a point-of-care platform launched by Randox Laboratories (Crumlin, UK) and Bosch Healthcare (Waiblingen, Germany ).

The SARS-CoV-2 pathogen detection test is currently the fastest PCR test (the gold standard of test methods) worldwide, and is predestined for decentralized use in mobile test centers in gas stations or airports, so that the test takers can obtain a reliable result while at the test site. The advantages of the rapid SARS-CoV-2 test in Vivalytic lie not only in the speed of the analysis, but also in the ease of use. A sample is taken from the nose or throat with a swab and placed in the test cartridge. The cartridge, containing all the reagents required for the test, is then inserted into the Vivalytic device for automated analysis. Available now in Europe, the CE-approved test, which has a sensitivity of 98% and a specificity of 100%, helps avoid quarantine time, ease labs, and make travel and work safer again.

“Rapid and accurate tests play a crucial role in identifying Covid-19 cases – to contain any outbreaks and limit the spread of the virus,” said Dr. Heather McMillan, Manager of Molecular Research and Development at Randox Biosciences. “This new rapid test will change the rules of the game in the coronavirus testing landscape by allowing patients to receive their results at the point of care faster than ever.”

“With our different coronavirus tests and variables analysis strategies, we open a range of test scenarios with a Vivalytic device, from screening to supportive differential diagnosis for similar symptoms,” added Marc Meier, President of Bosch Healthcare Solutions GmbH .

[ad_2]